Abivax SA Sponsored ADR (NASDAQ:ABVX) Given Average Recommendation of "Moderate Buy" by Brokerages

Key Points

• Analysts maintain a “Moderate Buy” consensus on Abivax, with 13 buy ratings, one hold and one sell among 15 brokerages. The average 12-month price target is $156.50, implying upside from the reported $116.52 share price.
• Several firms recently raised their price targets, including Morgan Stanley at $180, BTIG Research at $175 and Truist Financial at $155, while Wedbush maintained a neutral rating with a $110 target.
• Institutional investors own 47.91% of Abivax, with major increases from UBS and Morgan Stanley. The clinical-stage biotechnology company is developing obefazimod for ulcerative colitis and other inflammatory diseases.

Shares of Abivax SA Sponsored ADR (NASDAQ:ABVX - Get Free Report) have received an average rating of "Moderate Buy" from the fifteen brokerages that are presently covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell rating, one has given a hold rating and thirteen have given a buy rating to the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $156.50.

ABVX has been the subject of a number of research reports. Morgan Stanley reissued an "overweight" rating and issued a $180.00 price target on shares of Abivax in a research report on Friday, July 24th. Wedbush lifted their target price on Abivax from $90.00 to $110.00 and gave the stock a "neutral" rating in a research report on Tuesday, June 30th. Guggenheim reissued a "buy" rating on shares of Abivax in a report on Tuesday, June 30th. BTIG Research upped their target price on Abivax from $150.00 to $175.00 and gave the company a "buy" rating in a research report on Tuesday, June 30th. Finally, Truist Financial raised their price target on Abivax from $135.00 to $155.00 and gave the stock a "buy" rating in a research note on Thursday, July 2nd.

Hedge Funds Weigh In On Abivax

Hedge funds have recently modified their holdings of the business. UBS Group AG grew its position in Abivax by 2,561.0% during the 3rd quarter. UBS Group AG now owns 4,461,262 shares of the company's stock worth $378,761,000 after purchasing an additional 4,293,606 shares during the last quarter. Morgan Stanley raised its holdings in shares of Abivax by 114.3% in the fourth quarter. Morgan Stanley now owns 3,151,994 shares of the company's stock valued at $425,062,000 after buying an additional 1,681,277 shares during the last quarter. Paradigm Biocapital Advisors LP purchased a new stake in shares of Abivax in the third quarter valued at about $132,800,000. TCG Crossover Management LLC boosted its stake in shares of Abivax by 17.4% during the third quarter. TCG Crossover Management LLC now owns 7,111,596 shares of the company's stock worth $603,774,000 after buying an additional 1,055,000 shares during the period. Finally, Westfield Capital Management Co. LP acquired a new stake in shares of Abivax during the fourth quarter worth about $136,199,000. 47.91% of the stock is currently owned by hedge funds and other institutional investors.

Abivax Trading Down 1.2%

Shares of Abivax stock opened at $116.52 on Thursday. The company has a fifty day simple moving average of $123.85 and a 200-day simple moving average of $119.06. The stock has a market cap of $10.17 billion, a price-to-earnings ratio of -22.36 and a beta of 1.03. Abivax has a 12-month low of $69.81 and a 12-month high of $148.83.

Abivax Company Profile

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source